coiaward2010

Webinar: GENERIC TKIs IN CML

The Glivec patent expires in most countries latest on 21 Dec 2016.

The CML Advocates Network has been following the situation of TKI generics closely for 3 years, and has now provided a webinar which summarizes the current status.

This webinar answers some important questions, such as:

  • What are generics, and do they differentiate from innovator products?
  • Which generics of CML Tyrosine Kinase Inhibitors exist?
  • What do we know about efficacy and safety?
  • What information on CML generics is available to patients?
  • What has the patient advocacy community done so far?
  • What can patients and patient advocacy groups do about CML generics?

More can be found on our CML Advocates Network Knowledge Base on CML Generics at http://www.cmladvocates.net/generics.

If you want access to the slides, please contact Jan Geissler at .

Webstream via AuthorStream (allows to skip slides)

 

 

 

 

 

 

 

 

webinar


Olga Lucia Jimenez Community Builder Avatar   15.12.2016 (12:20:48)
Generic drugs for cml Yes No Would like to have access to the webinar
 
 
   
 

Please donate!

Please donate!

LogIn

Tweet Feed

ASHClinicalNews
British report finds room for improvement in standardizing BCR-ABL1 testing for chronic myeloid #leukemia #CML ow.ly/UzQf30b9MYS

Retweeted Thursday, 27 April 2017

cmlnet
Want to participate at @EHA_Hematology Congress next June? Apply until 29th April for an #EHA22 fellowship here… twitter.com/i/web/status/8…

Thursday, 27 April 2017

cmlnet
Looking forward to meet you at the 15th #CML Horizons Conference,Frankfurt,26-28 May. Follow us with #CMLHZ17 +Info… twitter.com/i/web/status/8…

Wednesday, 26 April 2017